Medical Health & Life Science Research News

New report examines the Asia Pacific alzheimer’s disease therapeutics and diagnostics market

New report examines the Asia Pacific alzheimer’s disease therapeutics and diagnostics market

Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics Market by Therapeutics (Marketed Drugs-(NMDA Receptor Antagonists, Cholinesterase Inhibitors), Pipeline Drugs), by Diagnostics (Computed tomography scan, Electroencephalography, Lumbar puncture test, Magnetic resonance imaging, Positron emission tomography, and Others) and by Region

- Advertising -

According to the report Asia Pacific Alzheimer’s disease Therapeutics and Diagnostics market, published by Market Data Forecast, the Asia Pacific market was worth USD 2.29 billion in 2016 and estimated to be growing at a CAGR of 5.02%, to reach USD 2.93 billion by 2021. Alzheimer’s disease is a neurodegenerative, progressive, non-reversible ailment that is caused due to irregular functioning of brain cells i.e.

breakdown of synaptic communication, ensuing in the loss of cerebral functions.

Certain signs and indications of Alzheimer’s disease are memory loss, sleeplessness, recurring movements, anxiety, despair and loss of reasoning capabilities.

- Advertising -

All memory and cerebral functioning may be lost in the advanced stages of the disease. According to the International Institute of Aging, Alzheimer’s disease is the most frequent form of dementia.

Browse market data tables and in-depth TOC of the Asia Pacific Alzheimer’s disease Therapeutics and Diagnostics Industry to 2021 at www.marketdataforecast.com/market-…50/request-sample

The growth of the Asia-Pacific Alzheimer’s disease Therapeutics and Diagnostics Market is mainly driven by factors such as rising geriatric populace, upsurge in healthcare spending and increasing government subsidy. In addition, growing healthcare cognizance and innovative diagnostic technologies are also stimulating the growth of the market.

However, several factors such as stringent regulations, long authorization time for new medicines, and expiration of numerous patent drugs are restraining the growth of the Alzheimer’s disease Therapeutics and Diagnostics market in this region.

Report: www.marketdataforecast.com/market-…50/request-sample

The Asia-Pacific Alzheimer’s Disease Therapeutics and Diagnostics market is segmented based on Therapeutics and Diagnostics. The market for Alzheimer’s disease Therapeutics and Diagnostics, on the basis of Therapeutics is segmented into Marketed Drugs and Pipeline Drugs.

Marketed Drugs are further segmented into NMDA Receptor Antagonists and Cholinesterase Inhibitors. Marketed Drugs lead the market on the basis of Therapeutics due to a large user base.

On the basis of Diagnostics, the Alzheimer’s disease Therapeutics and Diagnostics market is segmented into Computed tomography scan, Electroencephalography, Lumbar puncture test, Magnetic resonance imaging, Positron emission tomography, and Others. Under this segment, Computed tomography scan segment leads the Alzheimer’s disease Therapeutics and Diagnostics market.

Absence of alternative imaging tool for brain and neurological diagnostics is one of the crucial reasons for its large share.

The Asia-Pacific region is geographically segmented into China, India, Japan, South Korea, and Australia. Developing countries are anticipated to offer lucrative prospects for this market in this region.

According to Alzheimer’s disease International in 2015, 58% of people with dementia live in emerging countries, but by 2050 this figure will rise to 68%. The fastest growth in the elderly populace is taking place in China, India, and their south Asian and western Pacific region.

Report: www.marketdataforecast.com/market-…ket-2250/inquire

Leading companies have applied tactics such as mergers & acquisitions, collaborations, and joint ventures to gain a strong foothold in the market. The major companies dominating the Alzheimer’s Disease Therapeutics and Diagnostics market in this region are Abbvie Inc., Pfizer Inc., AC Immune SA, Eisai Co Ltd., Allergan PLC, Novartis AG, Amarantus Bioscience Holdings, H.

Lundbeck A/S, Anavex LifeSciences, Avid Radiopharmaceuticals, Forest Laboratories Inc., Axon Neuroscience, Daiichi Sankyo Co, TauRx Therapeutics Ltd, Eli Lilly, F. Hoffmann La Roche AG, Johnson & Johnson, GE Healthcare, Janssen Pharmaceuticals.

 

News From

Market Data Forecast - market research, business intelligence and consultingMarket Data Forecast
Category: Market Research Publishers and RetailersCompany profile: Market Data Forecast is a firm working in the areas of market research, business intelligence and consulting. We have rich experience in research and consulting for various business domains to cater to the needs of both individual and corporate clients. A few key business areas that we handle with excellence include business process improvement, corporate financing and decision making based on market research, assisting in developing appropriate strategy and providing consultancy based on extens ...